Literature DB >> 6405756

Antinuclear antibodies in localized scleroderma.

K Takehara, Y Moroi, Y Nakabayashi, Y Ishibashi.   

Abstract

When HeLa cells were used as the substrate for detection by the indirect immunofluorescence method, antinuclear antibodies were demonstrated in 16 of 22 (72.7%) sera from patients with localized scleroderma. When mouse kidney sections were used, the positive rate for antinuclear antibodies was 50% (11 of 22). In the 3 subgroups of localized scleroderma, frequencies of antinuclear antibodies on HeLa cells were as follows: morphea, 50% (2 of 4), generalized morphea, 100% (6 of 6), linear scleroderma, 67% (8 of 12). Antibodies to centromere, Scl-70, nuclear RNP, Sm, and SS-B antigens were not detected in any patients with localized scleroderma. The high frequency of antinuclear antibodies in localized scleroderma sera suggests that localized scleroderma is a disease which, though different from diffuse scleroderma, also involves an immunologic abnormality.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6405756     DOI: 10.1002/art.1780260506

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  22 in total

1.  Prevalence in myositis of antibodies recognizing anti-U3 RNA probably in a novel complex with 22/25 kD protein and not fibrillarin.

Authors:  M Kubo; H Ihn; M Kuwana; K Yamane; N Yazawa; K Tamaki
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

2.  Auto-immune disorders in localized scleroderma.

Authors:  R Rondinone; M Germino; E Sartori; C Veller Fornasa; A Ruffatti; C Betterle; A Peserico
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

3.  Elevated soluble CD23 levels in the sera from patients with localized scleroderma.

Authors:  S Sato; M Fujimoto; K Kikuchi; H Ihn; K Tamaki; K Takehara
Journal:  Arch Dermatol Res       Date:  1996-02       Impact factor: 3.017

4.  Localized scleroderma and hemiatrophy in association with antibodies to double-stranded DNA.

Authors:  A O Adebajo; A J Crisp; A Nicholls; B L Hazleman
Journal:  Postgrad Med J       Date:  1992-03       Impact factor: 2.401

5.  Frequency of antinuclear antibodies in mestizo Mexican children with morphea.

Authors:  Elizabeth Guevara-Gutiérrez; Janeth Yinh-Lao; Patricia García-Gutiérrez; Alberto Tlacuilo-Parra
Journal:  Clin Rheumatol       Date:  2010-06-14       Impact factor: 2.980

6.  Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis.

Authors:  H Ihn; K Yamane; N Yazawa; M Kubo; M Fujimoto; S Sato; K Kikuchi; K Tamaki
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

Review 7.  Development of minimum standards of care for juvenile localized scleroderma.

Authors:  Tamás Constantin; Ivan Foeldvari; Clare E Pain; Annamária Pálinkás; Peter Höger; Monika Moll; Dana Nemkova; Lisa Weibel; Melinda Laczkovszki; Philip Clements; Kathryn S Torok
Journal:  Eur J Pediatr       Date:  2018-05-04       Impact factor: 3.183

8.  Soluble CD4 and CD8 in serum from patients with localized scleroderma.

Authors:  S Sato; M Fujimoto; K Kikuchi; H Ihn; K Tamaki; K Takehara
Journal:  Arch Dermatol Res       Date:  1996-06       Impact factor: 3.017

9.  Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases.

Authors:  Justin J Leitenberger; Rachael L Cayce; Robert W Haley; Beverley Adams-Huet; Paul R Bergstresser; Heidi T Jacobe
Journal:  Arch Dermatol       Date:  2009-05

10.  Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma.

Authors:  H Ihn; S Sato; M Fujimoto; K Kikuchi; K Takehara
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.